Cigna earnings beat by $0.04, revenue topped estimates
SUNNYVALE, Calif. - Intuitive (NASDAQ:ISRG), a $189 billion medical technology leader with robust 19% year-over-year revenue growth, received U.S. Food and Drug Administration clearance for its Vessel Sealer Curved instrument designed for use with the company’s multiport da Vinci robotic surgical systems, according to a press release issued Thursday.
The new advanced bipolar electrosurgical instrument features a curved jaw profile and is the first of Intuitive’s advanced energy instruments to receive FDA clearance for lymphatic vessel transection. The device is designed to seal, cut, grasp, and dissect tissue. According to InvestingPro analysis, Intuitive maintains a strong financial health score of "GREAT," supporting its continued innovation in surgical technology.
The FDA cleared the instrument for grasping and blunt dissection of tissue, as well as bipolar coagulation and mechanical transection of blood vessels up to 7mm in diameter, lymphatic vessels, and tissue bundles that fit within the instrument’s jaws.
"We designed Vessel Sealer Curved to give surgeons greater precision in narrow anatomical spaces," said Iman Jeddi, senior vice president and general manager of da Vinci platforms & product operations at Intuitive.
According to the company, the instrument’s slim, curved jaw design follows natural anatomical contours to improve visibility and control in tight spaces and around critical structures. The mechanical blade cuts closer to the tip, offering additional versatility as a dissector.
The company noted that the instrument is not indicated for tubal sterilization or tubal coagulation procedures.
Intuitive, founded 30 years ago, reports that surgeons have performed nearly 17 million procedures using its da Vinci surgical systems, with approximately 90,000 surgeons trained on the technology. With an impressive gross profit margin of 67% and consistent growth, InvestingPro data reveals 12 additional key insights about Intuitive’s market position and growth potential. Get the complete analysis and detailed Pro Research Report, available exclusively to subscribers.
In other recent news, Intuitive Surgical received early CE mark approval for its DV5 system in Europe, covering adult and pediatric use for various minimally invasive procedures. This regulatory milestone was achieved ahead of the company’s projected year-end 2025 timeline, as noted by Leerink Partners, who maintained an Outperform rating with a $539.00 price target. Meanwhile, Deutsche Bank downgraded Intuitive Surgical from Hold to Sell, adjusting the price target to $440, reflecting a revised outlook on the company’s market position. In contrast, Erste Group upgraded the stock from Hold to Buy, anticipating improved turnover and profits by 2025, despite a current slowdown due to tariffs on products manufactured in Mexico. Bernstein SocGen Group reiterated their Outperform rating, highlighting the company’s promising product cycle and potential for substantial earnings growth. Additionally, Intuitive Surgical announced a leadership transition, with Dave Rosa set to become CEO on July 1, 2025, succeeding Gary Guthart, who will become Executive Chair of the Board. This planned succession underscores Rosa’s contributions to the company’s strategic direction and product development. Intuitive Surgical is also celebrating its 30th anniversary, marking significant milestones in minimally invasive care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.